| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||
Net loss | ||||||||
-7,038 | -28,890 | -24,448 | -18,332 | -11,069 | -5,757 | -8,407 | -13,591 | -9,859 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Accretion on marketable securities | ||||||||
-71 | 119 | 276 | 378 | 247 | - | - | - | - |
Depreciation and amortization expense | ||||||||
34 | 35 | 35 | 28 | 27 | 25 | 24 | 22 | 9 |
Stock-based compensation expense | ||||||||
975 | 886 | 1,201 | 944 | 663 | 581 | 629 | 402 | 1,181 |
Changes in operating assets and liabilities: | ||||||||
Restricted cash | ||||||||
- | - | - | - | - | - | 0 | 0 | 84 |
Prepaid expenses and other current assets | ||||||||
-542 | -2,239 | 727 | 1,705 | 81 | -139 | -804 | 1,309 | 264 |
Accounts payable | ||||||||
-5,506 | -3,248 | 1,778 | 5,053 | 144 | -1,210 | -312 | 3,039 | 80 |
Accrued liabilities | ||||||||
-4,128 | 3,263 | 756 | 219 | -1,482 | -636 | -3,205 | 1,714 | 1,105 |
Funding advance | ||||||||
- | - | - | - | - | - | 0 | 0 | 500 |
Other liabilities | ||||||||
9 | 9 | -5 | -4 | -4 | -3 | -3 | -3 | 28 |
Net cash used in operating activities | ||||||||
-15,041 | -25,646 | -21,651 | -14,336 | -12,049 | -7,645 | -10,718 | -9,783 | -7,304 |
Purchases of property and equipment | ||||||||
- | 30 | 193 | 24 | 24 | 29 | 29 | 26 | 278 |
Maturities of marketable securities | ||||||||
42,500 | 36,000 | 38,000 | 25,000 | 42,500 | - | - | - | - |
Purchases of marketable securities | ||||||||
- | -1 | 20,000 | 0 | 77,104 | - | - | - | - |
Net cash provided by (used in) investing activities | ||||||||
42,500 | 35,971 | 17,807 | 24,976 | -34,628 | -8,090 | -17,779 | -74,569 | -278 |
Proceeds from public offering, net of issuance costs | ||||||||
- | -1 | 0 | 2,932 | 46,816 | 970 | 0 | 0 | 89,938 |
Taxes paid related to net share settlement of restricted stock units | ||||||||
1 | - | - | - | - | - | - | - | - |
Net cash (used in) provided by financing activities | ||||||||
-1 | -11 | 6,094 | 3,550 | 46,816 | 5 | 0 | 0 | 89,938 |
Net increase in cash, cash equivalents and restricted cash | ||||||||
27,458 | - | - | - | 139 | - | - | - | - |
Net increase (decrease) in cash and cash equivalents | ||||||||
- | - | - | - | - | - | -28,497 | -84,352 | 82,356 |
Supplemental disclosure of non-cash investing and financing activities: | ||||||||
Purchases of property and equipment included in accounts payable | ||||||||
- | - | - | - | - | - | -10 | 4 | 8 |
Conversion of redeemable convertible preferred stock into common stock | ||||||||
- | - | - | - | - | 0 | 0 | 0 | 81,620 |
Issuance costs associated with public offering included in accounts payable | ||||||||
- | - | - | - | 231 | - | - | - | - |